Terata Kaori, Motoyama Satoru, Kamata Shuichi, Hinai Yudai, Miura Masatomo, Sato Yusuke, Yoshino Kei, Ito Aki, Imai Kazuhiro, Saito Hajime, Minamiya Yoshihiro
Division of Brest Surgery, Akita Red Cross Hospital, Akita, Japan.
Tumour Biol. 2014 Jun;35(6):5931-5. doi: 10.1007/s13277-014-1786-3. Epub 2014 Mar 16.
Lymph node status is a key indicator of the best approach to treatment of invasive breast cancer. However, the accuracy with which lymph node metastasis is diagnosed is not currently satisfactory. New and more reliable methods that enable one to know who has a greater potential for lymph node metastasis would be highly desirable. We previously reported that lymph node involvement in esophageal and lung cancer may have a genetic component: C-reactive protein (CRP) 1846C>T genetic polymorphism. Here we examined the diagnostic value of CRP 1846C>T polymorphism for assessing the risk of lymph node metastasis in cases of invasive breast cancer. The study participants were 185 women with invasive breast cancer who underwent curative surgery with lymph node dissection. Using DNA from blood samples and polymerase chain reaction-restriction fragment length polymorphism, the utility of CRP genetic 1846C>T polymorphism (rs1205) for assessing the risk of lymph node metastasis was evaluated. Fifty-two (28 %) patients had lymph node metastasis. After the patients were divided into two groups based on their CRP 1846 genotypes (C/C+C/T and T/T), the clinical characteristics did not differ between the groups, but there was a significantly greater incidence of lymph node metastasis among patients in the T/T group. Moreover, the odds ratio for lymph node involvement in patients carrying the 1846 T/T genotype was more than 2.2 in multivariate logistic regression models. CRP genetic polymorphism may be a novel predictor of the risk of lymph node metastasis in invasive breast cancer.
淋巴结状态是浸润性乳腺癌最佳治疗方法的关键指标。然而，目前诊断淋巴结转移的准确性并不令人满意。非常需要新的、更可靠的方法来确定谁有更高的淋巴结转移可能性。我们之前报道过，食管癌和肺癌中的淋巴结受累可能有遗传因素：C反应蛋白（CRP）1846C>T基因多态性。在此，我们研究了CRP 1846C>T多态性对评估浸润性乳腺癌患者淋巴结转移风险的诊断价值。研究对象为185例接受了淋巴结清扫根治性手术的浸润性乳腺癌女性患者。利用血样中的DNA和聚合酶链反应-限制性片段长度多态性技术，评估了CRP基因1846C>T多态性（rs1205）对评估淋巴结转移风险的实用性。52例（28%）患者发生了淋巴结转移。根据患者的CRP 1846基因型（C/C+C/T和T/T）将患者分为两组后，两组的临床特征无差异，但T/T组患者的淋巴结转移发生率显著更高。此外，在多因素逻辑回归模型中，携带1846 T/T基因型患者发生淋巴结受累的比值比超过2.2。CRP基因多态性可能是浸润性乳腺癌淋巴结转移风险的一种新的预测指标。
